Skip to content

Pasireotide

Signifor Lar, Signifor (pasireotide) is a protein pharmaceutical. Pasireotide was first approved as Signifor Lar on 2012-04-24. It is used to treat cushing syndrome in the USA. It has been approved in Europe to treat acromegaly and pituitary acth hypersecretion. The pharmaceutical is active against somatostatin receptor type 3, somatostatin receptor type 1, somatostatin receptor type 2, and somatostatin receptor type 5. Signifor's patents are valid until 2028-05-23 (FDA).
Trade Name Signifor
Common Name Pasireotide
Indication acromegaly, cushing syndrome, pituitary acth hypersecretion
Drug Class Peptides: inhibition of growth hormone release
Pasireotide
Get full access now